| abstract |
A modified antibody or antigen-binding fragment thereof to the extracellular domain of human prostate specific membrane antigen (PSMA) is provided. Modified anti-PSMA antibodies, or antigen-binding fragments thereof, are rendered weakly immunogenic compared to their unmodified counterparts against certain species, such as humans. Also disclosed are pharmaceutical compositions comprising the above antibodies, nucleic acids, recombinant expression vectors and host cells for making such antibodies and fragments. Also provided are methods of using the antibodies of the invention in vitro or in vivo to detect human PSMA or to remove or kill PSMA-expressing cells, such as cancer or prostate cells that express PSMA. |